1. Home
  2. ZNB vs GRI Comparison

ZNB vs GRI Comparison

Compare ZNB & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zeta Network Group Class A Ordinary Shares

ZNB

Zeta Network Group Class A Ordinary Shares

N/A

Current Price

$0.43

Market Cap

2.8M

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$1.20

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZNB
GRI
Founded
2002
2018
Country
China
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
3.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
ZNB
GRI
Price
$0.43
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $18.50
AVG Volume (30 Days)
★ 2.6M
38.8K
Earning Date
10-19-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.10
$0.18
52 Week High
$9.78
$64.12

Technical Indicators

Market Signals
Indicator
ZNB
GRI
Relative Strength Index (RSI) 35.09 34.98
Support Level $0.22 N/A
Resistance Level $1.93 $2.66
Average True Range (ATR) 0.21 0.18
MACD -0.01 -0.04
Stochastic Oscillator 6.67 2.16

Price Performance

Historical Comparison
ZNB
GRI

About ZNB Zeta Network Group Class A Ordinary Shares

Zeta Network Group consist principally of cryptocurrency mining. The company conducts business as two operating segments which comprise of consulting services and cryptocurrency mining. Majority of revenue comes from cryptocurrency mining segment.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: